IRF1 and cervical cancer: A separate group investigated the sensitivity of cisplatin therapy of cervical SCC cells and found that while STAT3 phosphorylation dramatically increased in pre-cancerous cervical cancer legions, it declined when comparing to cervical SCC, and cervical SCC cells pre-treated with OSM were more responsive toward cisplatin-based chemoradiotherapy, via upregulation of STAT3-mediated interferon-regulatory factor 1 (IRF1) expression (246, 247).